These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23188559)

  • 1. Two retroviruses packaged in one cell line can combined inhibit the replication of HIV-1 in TZM-bl cells.
    Liang Z; Guo Z; Wang X; Kong X; Liu C
    Virol Sin; 2012 Dec; 27(6):339-44. PubMed ID: 23188559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
    Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
    J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
    Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo.
    Yamada E; Nakaoka S; Klein L; Reith E; Langer S; Hopfensperger K; Iwami S; Schreiber G; Kirchhoff F; Koyanagi Y; Sauter D; Sato K
    Cell Host Microbe; 2018 Jan; 23(1):110-120.e7. PubMed ID: 29324226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
    Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
    Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetherin/BST-2: Restriction Factor or Immunomodulator?
    Li SX; Barrett BS; Guo K; Santiago ML
    Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
    Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
    Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
    Kühl A; Banning C; Marzi A; Votteler J; Steffen I; Bertram S; Glowacka I; Konrad A; Stürzl M; Guo JT; Schubert U; Feldmann H; Behrens G; Schindler M; Pöhlmann S
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S850-60. PubMed ID: 21987761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.
    Kuhl BD; Cheng V; Donahue DA; Sloan RD; Liang C; Wilkinson J; Wainberg MA
    PLoS One; 2011; 6(11):e27660. PubMed ID: 22110710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
    Ali MS; Hammonds J; Ding L; Spearman P
    PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
    Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
    mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.